Jump to content

Troxacitabine

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by JBW3 (talk | contribs) at 11:26, 23 March 2018 (Reverting editing by a block-evading sockpuppet). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Troxacitabine
Identifiers
  • 4-amino-1-[(2S,4S)-2-(hydroxymethyl)-1,3-dioxolan-4-yl]pyrimidin-2(1H)-one
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC8H11N3O4
Molar mass213.19 g/mol g·mol−1
3D model (JSmol)
  • O=C1/N=C(/N)\C=C/N1[C@H]2O[C@H](OC2)CO
  • InChI=1S/C8H11N3O4/c9-5-1-2-11(8(13)10-5)6-4-14-7(3-12)15-6/h1-2,6-7,12H,3-4H2,(H2,9,10,13)/t6-,7-/m0/s1 checkY
  • Key:RXRGZNYSEHTMHC-BQBZGAKWSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Troxacitabine (brand name Troxatyl) is a nucleoside analogue with anticancer activity. Its use is being studied in patients with refractory lymphoproliferative diseases.[1]

References

  1. ^ Vose, Julie M.; Panwalkar, Amit; Belanger, Robert; Coiffier, Bertrand; Baccarani, Michele; Gregory, Stephanie A.; Facon, Thierry; Fanin, Renato; Caballero, Dolores; Ben-Yehuda, Dina; Giles, Francis (2007). "A phase II multicenter study of troxacitabine in relapsed or refractory lymphoproliferative neoplasms or multiple myeloma". Leukemia & Lymphoma. 48 (1): 39–45. doi:10.1080/10428190600909578.